What's in Sunnybrook Health Sciences Centre's pipeline?

Sunnybrook Health Sciences Centre has 28 drugs in our index: 8 marketed, 0 filed, 9 in Phase 3, 6 in Phase 2, 5 in Phase 1.

Which companies overlap with Sunnybrook Health Sciences Centre's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Second Affiliated Hospital, School of Medicine, Zhejiang University, NYU Langone Health, Hoffmann-La Roche, Biogen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sunnybrook-health-sciences-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sunnybrook Health Sciences Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sunnybrook Health Sciences Centre pipeline: 8 marketed, 0 filed, 9 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 9 Phase 3 6 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
citalopram (celexa)	citalopram (celexa)	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)	Psychiatry / Mental Health
Placebo (cornstarch)	Placebo (cornstarch)	marketed
Methoxyflurane, MEOF	Methoxyflurane, MEOF	marketed	Volatile halogenated ether anesthetic	GABA receptors, NMDA receptors	Anesthesia, Acute Pain Management
Sevoflurane inhalant product	Sevoflurane inhalant product	marketed	Volatile inhalational anesthetic	GABA-A receptor, NMDA glutamate receptor	Anesthesiology
ticagrelor + aspirin	ticagrelor + aspirin	marketed	Dual antiplatelet therapy	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)	Cardiovascular
Acetylsalicylic Acid (ASA)	Acetylsalicylic Acid (ASA)	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)	Cardiovascular; Pain management; Inflammation
Withania somnifera	Withania somnifera	marketed
Perflutren lipid microsphere	Perflutren lipid microsphere	marketed
modified PENTOCLO (mPENTOCLO)	modified PENTOCLO (mPENTOCLO)	phase 3			Infectious Disease
No tranexamic acid	No tranexamic acid	phase 3	Antifibrinolytic agent	Plasminogen	Hematology / Hemostasis
Cholinesterase Inhibitor	Cholinesterase Inhibitor	phase 3	Cholinesterase inhibitor	Acetylcholinesterase	Neurology
Variation in volume of local anesthetic	Variation in volume of local anesthetic	phase 3			Anesthesiology / Pain Management

Therapeutic area mix

Cardiovascular · 4
Anesthesiology · 2
Cardiovascular; Pain management; Inflammation · 1
Critical Care · 1
Hematology / Hemostasis · 1
Infectious Disease · 1
Neurology · 1
Oncology, Infectious Diseases · 1
Oncology, Nephrology · 1
Anesthesia, Acute Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Second Affiliated Hospital, School of Medicine, Zhejiang University · 3 shared drug classes
NYU Langone Health · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Biogen · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Massachusetts General Hospital · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sunnybrook Health Sciences Centre:

Cite this brief

Drug Landscape (2026). Sunnybrook Health Sciences Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sunnybrook-health-sciences-centre. Accessed 2026-05-16.